Wyeth Wins Bench Trial and Permanent Injunction in Trade Secret Misappropriation Case

Wyeth, a global pharmaceutical company acquired by Pfizer in 2009, won a bench trial and permanent injunction in a trade secret misappropriation case in the District of Minnesota involving Wyeth’s trade secret chemical process for manufacturing Premarin®, a drug with sales in excess of $1 billion. The district court entered a permanent injunction preventing the competitor from entering the market with the first generic version of the drug. The decision was later upheld on appeal.